OwlTail

Cover image of Kurt Schalper

Kurt Schalper

9 Podcast Episodes

Latest 6 Nov 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

59mins

17 Nov 2020

Episode artwork

Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

59mins

17 Nov 2020

Similar People

Episode artwork

Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

58mins

17 Nov 2020

Episode artwork

Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice

1hr 22mins

1 Apr 2020

Most Popular

Episode artwork

Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice

1hr 22mins

1 Apr 2020

Episode artwork

Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice

1hr 22mins

1 Apr 2020

Episode artwork

Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

52mins

14 Dec 2018

Episode artwork

Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

52mins

14 Dec 2018

Episode artwork

Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

PeerView Clinical Pharmacology CME/CNE/CPE Video

Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

52mins

14 Dec 2018